Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
14.40
+0.60 (4.35%)
At close: Aug 21, 2025, 4:00 PM
14.68
+0.28 (1.94%)
After-hours: Aug 21, 2025, 5:14 PM EDT

Company Description

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients.

Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors.

The company is headquartered in Waltham, Massachusetts.

Crescent Biopharma, Inc.
Crescent Biopharma logo
CountryUnited States
Founded2003
IndustryBiotechnology
SectorHealthcare
Employees6
CEOJoshua Brumm

Contact Details

Address:
300 5th Avenue
Waltham, Massachusetts 02451
United States
Phone617-430-5595
Websitecrescentbiopharma.com

Stock Details

Ticker SymbolCBIO
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001124105
CUSIP Number14888D208
ISIN NumberUS4037831033
Employer ID56-2020050
SIC Code2834

Key Executives

NamePosition
Joshua T. BrummChief Executive Officer and Director
Dr. Jonathan McNeill M.D.President and Chief Operating Officer
Richard William Scalzo M.B.A.Chief Financial Officer
Ryan LynchSenior Vice President of Finance, Treasurer and Chief Accounting Officer
Dr. Jan Pinkas Ph.D.Chief Scientific Officer
Barbara H. Bispham J.D.General Counsel and Corporate Secretary
Amy ReillyChief Communications Officer
Christopher DoughtyChief Business Officer
Dr. Wenjie Cheng Ph.D.Senior Vice President of Technical Operations
Dr. Ellie Im M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Aug 11, 202510-QQuarterly Report
Aug 11, 20258-KCurrent Report
Jun 6, 20258-KCurrent Report
May 23, 20258-KCurrent Report
May 23, 2025424B5Filing
May 22, 2025424B5Filing
May 22, 20258-KCurrent Report
May 9, 202510-QQuarterly Report
May 9, 20258-KCurrent Report
Apr 28, 20258-KCurrent Report